Patel Featured on Patent Hurdles Faced by Biosimilars to Get to Market

Hatch-Waxman and Biosimilars Practice Group Co-Leader Sailesh Patel is featured in a virtual panel Q&A on the patent and antitrust hurdles that biosimilars face on the path to the marketplace.

Sal weighs in on topics and trends, including drug interchangeability as the single biggest hurdle to biosimilars, an increasingly popular Hatch-Waxman settlement strategy that staggers entry dates for biosimilar applicants, and how the 2019 guidance on patent eligibility could lead to a higher barrier to entry for biosimilars in the U.S.

Read the full discussion here.